About DnaJ homolog subfamily B member 4
DnaJ homolog subfamily B member 4 (DNAJB4) is a protein
from Homo sapiens identified by UniProt accession
Q9UDY4, 337 residues long.
MolForge cross-references it against 0 known binders and
428 disease associations.
Target properties
| Protein name | DnaJ homolog subfamily B member 4 |
|---|
| UniProt accession | Q9UDY4 |
|---|
| Gene | DNAJB4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 337 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (428)
Diseases linked to this target (Open Targets).
- congenital myopathy 21 with early respiratory failure · score 0.57
- lean body mass · score 0.41
- fat body mass · score 0.38
- body height · score 0.36
- body weight · score 0.36
- appendicular lean mass · score 0.33
- body mass index · score 0.32
- base metabolic rate measurement · score 0.27
- whole body water mass · score 0.27
- alkaline phosphatase measurement · score 0.25
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UDY4-F1 | alphafold | PREDICTED | 82.72 | — |
Amino-acid sequence (337 residues)
MGKDYYCILG IEKGASDEDI KKAYRKQALK FHPDKNKSPQ AEEKFKEVAE AYEVLSDPKK REIYDQFGEE GLKGGAGGTD GQGGTFRYTF HGDPHATFAA FFGGSNPFEI FFGRRMGGGR DSEEMEIDGD PFSAFGFSMN GYPRDRNSVG PSRLKQDPPV IHELRVSLEE IYSGCTKRMK ISRKRLNADG RSYRSEDKIL TIEIKKGWKE GTKITFPREG DETPNSIPAD IVFIIKDKDH PKFKRDGSNI IYTAKISLRE ALCGCSINVP TLDGRNIPMS VNDIVKPGMR RRIIGYGLPF PKNPDQRGDL LIEFEVSFPD TISSSSKEVL RKHLPAS
Explore DnaJ homolog subfamily B member 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets